HK1208817A1 - Chromane compounds - Google Patents

Chromane compounds

Info

Publication number
HK1208817A1
HK1208817A1 HK15109582.8A HK15109582A HK1208817A1 HK 1208817 A1 HK1208817 A1 HK 1208817A1 HK 15109582 A HK15109582 A HK 15109582A HK 1208817 A1 HK1208817 A1 HK 1208817A1
Authority
HK
Hong Kong
Prior art keywords
chromane compounds
chromane
compounds
Prior art date
Application number
HK15109582.8A
Other languages
English (en)
Chinese (zh)
Inventor
Ryosuke Munakata
Makoto Inoue
Hiroaki Tominaga
Shingo Yamasaki
Yasuhiro Shiina
Kiyohiro Samizu
Hisao Hamaguchi
Lin Hong
Original Assignee
Comentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Comentis Inc filed Critical Comentis Inc
Publication of HK1208817A1 publication Critical patent/HK1208817A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
HK15109582.8A 2012-05-30 2015-09-29 Chromane compounds HK1208817A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653321P 2012-05-30 2012-05-30
US201361782038P 2013-03-14 2013-03-14
PCT/US2013/043016 WO2013181202A2 (fr) 2012-05-30 2013-05-29 Composés de chromane

Publications (1)

Publication Number Publication Date
HK1208817A1 true HK1208817A1 (en) 2016-03-18

Family

ID=49674034

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109582.8A HK1208817A1 (en) 2012-05-30 2015-09-29 Chromane compounds

Country Status (15)

Country Link
US (2) US8975415B2 (fr)
EP (1) EP2854797A4 (fr)
JP (1) JP2015518048A (fr)
KR (1) KR20150023536A (fr)
CN (1) CN104394862A (fr)
AR (1) AR091203A1 (fr)
AU (1) AU2013267555A1 (fr)
BR (1) BR112014029597A2 (fr)
CA (1) CA2873678A1 (fr)
EA (1) EA026380B1 (fr)
HK (1) HK1208817A1 (fr)
MX (1) MX2014014066A (fr)
SG (1) SG11201407796YA (fr)
TW (1) TW201408672A (fr)
WO (1) WO2013181202A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104394862A (zh) 2012-05-30 2015-03-04 科门蒂斯公司 色满化合物
AR102202A1 (es) 2014-10-07 2017-02-08 Astrazeneca Ab Compuestos de oxazol y su uso como inhibidores de bace de oxazol
CN110790753B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林对甲苯磺酸盐、其制备方法和应用
CN110713483B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林中间体及艾拉普林的制备方法
CN110818694B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体及其应用
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482233T1 (de) 1999-06-28 2010-10-15 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
AU2004299040A1 (en) 2003-12-15 2005-06-30 Pharmacopeia, Inc. Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2007100536A1 (fr) 2006-02-24 2007-09-07 Wyeth COMPOSES DE DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] POUR L'INHIBITION DE LA β-SECRETASE
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
WO2010013302A1 (fr) * 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dérivé de spiroaminodihydrothiazine
CN102105475B (zh) * 2008-07-28 2014-04-09 卫材R&D管理有限公司 螺氨基二氢噻嗪衍生物
EP2324032B1 (fr) * 2008-08-19 2014-10-01 Vitae Pharmaceuticals, Inc. Inhibiteurs de la bêta-sécrétase
ES2459195T3 (es) 2008-09-11 2014-05-08 Amgen Inc. Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso
MX2011009571A (es) * 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
WO2011072064A1 (fr) * 2009-12-08 2011-06-16 Array Biopharma Inc. Spiro[chromane-4,4'-imidazol]ones en tant qu'inhibiteurs de bêta-sécrétase
JP5828848B2 (ja) * 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
EP2547685A1 (fr) * 2010-03-15 2013-01-23 Amgen Inc. Composés spiro tétracycliques en tant que modulateurs de la béta-sécrétase
CA2791389C (fr) * 2010-03-15 2014-04-29 Amgen Inc. Composes spiro de l'amino-dihydrooxazine et de l'amino-dihydrothiazine en tant que modulateurs de la beta-secretase et utilisation medicale associee
WO2011123674A1 (fr) * 2010-03-31 2011-10-06 Array Biopharma Inc. Composés pour traiter des maladies neurodégénératives
WO2011130741A1 (fr) 2010-04-16 2011-10-20 Array Biopharma Inc. Composés pour le traitement de maladies neurodégénératives
TW201219400A (en) 2010-09-24 2012-05-16 Array Biopharma Inc Compounds for treating neurodegenerative diseases
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β－分泌酶活性之噁二唑化合物及其使用方法
US20120157448A1 (en) 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
US8957083B2 (en) 2010-11-23 2015-02-17 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2012109165A1 (fr) 2011-02-07 2012-08-16 Amgen Inc. Composés de 5-amino-oxazépine et 5-amino-thiazépane en tant qu'antagonistes de la bêta-sécrétase et leurs procédés d'utilisation
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
CN104394862A (zh) 2012-05-30 2015-03-04 科门蒂斯公司 色满化合物
EP2669286A1 (fr) 2012-05-31 2013-12-04 Ares Trading S.A. Dérivés de spiro tétrahydro-benzothiophène utiles pour le traitement de maladies neuro-dégénératives

Also Published As

Publication number Publication date
BR112014029597A2 (pt) 2017-11-07
WO2013181202A2 (fr) 2013-12-05
SG11201407796YA (en) 2014-12-30
TW201408672A (zh) 2014-03-01
EA201492271A1 (ru) 2015-10-30
MX2014014066A (es) 2015-03-19
EP2854797A4 (fr) 2016-01-13
JP2015518048A (ja) 2015-06-25
EP2854797A2 (fr) 2015-04-08
KR20150023536A (ko) 2015-03-05
US8975415B2 (en) 2015-03-10
EA026380B1 (ru) 2017-04-28
AR091203A1 (es) 2015-01-21
CN104394862A (zh) 2015-03-04
AU2013267555A1 (en) 2014-12-04
CA2873678A1 (fr) 2013-12-05
US20140179695A1 (en) 2014-06-26
US20150225386A1 (en) 2015-08-13
US9242973B2 (en) 2016-01-26
WO2013181202A3 (fr) 2014-01-30

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
HK1245780B (zh) 咪唑並吡咯烷酮化合物
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (fr) Composés pro-neurogéniques
HK1206726A1 (en) Imidazotriazinone compounds
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
ME02404B (fr) Composés tétrahydropyrrolothiazines
HK1211283A1 (en) Compounds
HK1208817A1 (en) Chromane compounds
GB201209096D0 (en) Compounds
HK1206356A1 (en) Lpar - substituted cyanopyrazole compounds lpar-
HK1197062A1 (en) Chromene compound
GB201219820D0 (en) Compounds
GB201217310D0 (en) Compounds
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218758D0 (en) Compounds
GB201218776D0 (en) Compounds
GB201218774D0 (en) Compounds